Sales in Dr Reddy's generics business fell 8.6% to 966m rupees. Research and development of new drugs is continuing apace, with R&D spending rising 37% to 705m rupees - a key cause of the decrease in profits alongside the fall in sales. Profits slide at India's Dr ReddyProfits at Indian drugmaker Dr Reddy's fell 93% as research costs rose and sales flagged. Patents on a number of well-known products are due to run out in the near future, representing an opportunity for Dr Reddy, whose shares are listed in New York, and other Indian generics manufacturers. Dr Reddy's has built its reputation on producing generic versions of big-name pharmaceutical products.